By downregulating MCL1 and inducing the expression of the pro-death proteins NOXA and PUMA, azacytidine inhibits synergistically the pro-survival proteins MCL1 and BCL-XL, increasing the dependence of leukemia cells on BCL-2. Here, BCL2 is linked to leukemia.